Aripiprazole for schizophrenia. Systematic review.
2006
Background Aripiprazole is an atypical antipsychotic that is
reported to be effective in the treatment of schizophrenia. Aims To investigate the effects of aripiprazole on patients with
schizophrenia and schizophrenia-like psychoses by conducting a systematic
review of randomised controlled trials (RCTs). Method Database and manual searches and direct contact were used to
identify relevant RCTs. Results We included 10 randomised controlled studies (involving a
total of 4125 patients), but study attrition waslarge and the standard of data
reporting was poor. Compared with placebo, aripiprazole treatment was
associated with a significant decrease in relapse rates, increased compliance
with the study protocol, and a decrease in prolactin levels below the expected
values. Compared with risperidone, aripiprazole caused less elevation of
prolactin levels and less prolongation of the average QTc interval. Conclusions Aripiprazole has been licensed despite the fact that few
reliable data on this drug are publicly available. It may be effective for
treatment of schizophrenia, but in terms of tolerability and global outcomes
it shows little difference from existing antipsychotics.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
11
References
53
Citations
NaN
KQI